Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Idiopathic Retroperitoneal Fibrosis
NCT04762784Phase 4Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2020
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in Idiopathic retroperitoneal fibrosis (RPF) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Remission at 5 years. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
Idiopathic retroperitoneal fibrosis (RPF)
Beyond the preview
Go deeper on NCT04762784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762784.